Clinical Trials Logo

Depressive Disorder clinical trials

View clinical trials related to Depressive Disorder.

Filter by:

NCT ID: NCT05076643 Recruiting - Depression Clinical Trials

Biomarkers, TCM Body Constitution, Dietary Pattern and Psychological Factors in Predicting Depression

Start date: March 17, 2022
Phase:
Study type: Observational

This study aims to determine the predictors of depression among university students in Universiti Tunku Abdul Rahman (UTAR) Sungai Long Campus.

NCT ID: NCT05076214 Recruiting - Clinical trials for Depressive Disorder, Major

Aerobic Versus Leisure Group for Adolescents With Depression

Start date: February 28, 2022
Phase: N/A
Study type: Interventional

The aim is to evaluate aerobic group exercise versus leisure group activities in adolescents with mild to moderate depression. Primary outcome is Children's Depression Rating Scale - Revised (CDRS-R). Secondary outcomes are Clinical Global Impressions - Severity and Improvement scales (CGI), self-reported Quick Inventory of Depression Symptomatology (QIDS- A17-SR), the self-reported Outcome Rating Scale (ORS), clinician rated Children Global Assessment Scale (C-GAS), aerobic capacity (VO2max), muscular strength, body, Body Mass Index (BMI), presence or activity of selected biological markers of neuroprotection and neuroinflammation in blood samples and a cost evaluation rated by parents with Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness - Child version (Tic-P) and the Child Health Utility (CHU9D) to facilitate estimation of Quality Adjusted Life Years. Further objectives are qualitative interviews to explore adolescents' experiences of the intervention as well as how their health and lifestyle are influenced and a validation of QIDS- A17-C and QIDS- A17-SR versus CDRS-R will be performed.

NCT ID: NCT05075629 Completed - Depression Clinical Trials

Anxiety, Depression and Substance Use in Undergraduate Health Science Students During the Covid-19 Pandemic.

Start date: October 12, 2021
Phase:
Study type: Observational

A study will be conducted with a quantitative approach with correlational scope, observational analytical study, prospective cross-sectional. The objective is to compare the levels of anxious symptomatology, depressive symptomatology and substance use in university students who were exposed to SARS-CoV-2 with those who were not.

NCT ID: NCT05072210 Completed - Depression Clinical Trials

Mobile Interventions for the Prevention and Detection of Distress

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

Stress, anxiety, distress and depression are exceptionally high among healthcare providers at the frontline of the COVID-19 pandemic. Knowledge of factors underlying distress and resilience and evidence based interventions to impact the mental wellbeing of frontline healthcare providers is limited. This study will evaluate a novel mobile platform to gather the "distress experience" of healthcare workers at Unity Health Toronto in real time during and after the COVID-19 pandemic, use automated personalized mobile interventions (e.g. routine, sleep, exercise) to nudge active/passive parameters to manage distress.

NCT ID: NCT05066672 Recruiting - Clinical trials for Treatment Resistant Depression

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

Start date: February 28, 2022
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of NV-5138 in adults with TRD

NCT ID: NCT05065580 Completed - Clinical trials for Major Depressive Disorder

OMT as an Adjunctive Treatment in MDD

Start date: March 12, 2021
Phase: N/A
Study type: Interventional

participants will be receiving OMT 1x/week for 8 weeks. Each appointment with be a duration of 30 minutes. Patients will be required to fill out PHQ-9 and SSS-8 questionnaires before beginning the study and following the conclusion of the study.

NCT ID: NCT05065476 Completed - Depression Clinical Trials

Assessing the Impact of Isha Kriya Meditation on Anxiety and Depression - a Pilot Study

Start date: May 1, 2021
Phase:
Study type: Observational

This study aims to assess the impact of Isha Kriya, a freely available guided meditation, on mental health - specifically anxiety and depression.

NCT ID: NCT05061719 Enrolling by invitation - Clinical trials for Major Depressive Disorder

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Start date: October 8, 2021
Phase: Phase 3
Study type: Interventional

This is a multicenter, open-label, fixed dose, 26 week study of patients with MDD. Eligible patients from the lead-in studies will enter the Open-label Safety Study at the Screening/Baseline Visit (Visit 1/Day 1), at which point patient eligibility will be assessed and informed consent obtained.

NCT ID: NCT05061706 Active, not recruiting - Clinical trials for Major Depressive Disorder

Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Start date: September 30, 2021
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

NCT ID: NCT05060549 Not yet recruiting - Bipolar Depression Clinical Trials

Dopamine D3 Receptor Occupancy in Bipolar Depression

Start date: March 31, 2024
Phase: Phase 4
Study type: Interventional

Bipolar disorder is a common condition that can cause significant disability and risk for suicide. Second generation antipsychotic medications can be used to treat depression in bipolar disorder, yet we do not know how they work. Here, we will use a recently approved medication, cariprazine (Vraylar), to treat participants with bipolar depression. They will have brain imaging with PET scans before and during treatment to understand how the medication may be working. Particularly, we will look at the role of the D3 dopamine receptor.